Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for AMPE, TWTR and CNTA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Friday, 30 September 2022 02:40 PM

Levi & Korsinsky, LLP

NEW YORK, NY / ACCESSWIRE / September 30, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

AMPE Shareholders Click Here: https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=32302&wire=1
TWTR Shareholders Click Here: https://www.zlk.com/pslra-1/twitter-lawsuit-submission-form?prid=32302&wire=1
CNTA Shareholders Click Here: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=32302&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Friday, September 30, 2022, Press release picture

Ampio Pharmaceuticals, Inc. (NYSE:AMPE)

This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired Ampio common stock between December 29, 2020 and August 3, 2022, inclusive.
Lead Plaintiff Deadline : October 17, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=32302&wire=1

According to the filed complaint, (i) defendants had inflated the Company's true ability to successfully file a Biologics License Application ("BLA") for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Twitter, Inc. (NYSE:TWTR)

TWTR Lawsuit on behalf of: investors who purchased August 3, 2020 - August 23, 2022
Lead Plaintiff Deadline : November 14, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/twitter-lawsuit-submission-form?prid=32302&wire=1

According to the filed complaint, during the class period, Twitter, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Twitter knew about security concerns on their platform; (2) Twitter actively worked to hide the security concerns from the board, the investing public, and regulators; (3) contrary to representations in its filings with the U.S. Securities and Exchange Commission, Twitter did not take steps to improve security; (4) Twitter's active refusal to address security issues increased the risk of loss of public goodwill; and (5) as a result, defendants' statements about Twitter's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Centessa Pharmaceuticals plc (NASDAQ:CNTA)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022.
Lead Plaintiff Deadline : November 28, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=32302&wire=1

According to the filed complaint, (i) the Company's product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan's clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues; and (v) as a result, documents issued in connection with Centessa's initial public offering and the Company's public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Class Action
Back to newsroom
Back to Newsroom
Share by: